Graduate School of Life Science, Hokkaido University.
Department of Pharmacy, Hokkaido University Hospital.
Biol Pharm Bull. 2023;46(6):817-823. doi: 10.1248/bpb.b23-00013.
Vancomycin (VCM)-induced nephrotoxicity (VIN) is a major side effect in paediatric patients. However, most studies are limited to patients aged 0-18 years. We evaluated the risk factors of VIN in patients aged 0-1 year using Japanese electronic medical record database. We used RWD database which was contained electronic medical records and claims data of approximately 20 million people from 160 medical institutions. We targeted hospitalized patients who were administered VCM between June 2000 and December 2020. VIN was defined by two criteria: Criterion 1 was an increase in serum creatinine (Scr) ≥ 0.5 mg/dL or 50% during VCM treatment period compared to the Scr baseline; and criterion 2 was an increase in Scr ≥50% within seven days or Scr ≥0.3 mg/dL within two days during VCM treatment. The risk factors of VIN were evaluated using multivariate logistic regression analysis. We analysed 446 patients; patients with VIN in Criteria 1 and 2 were 33 and 58, respectively. In Criterion 1, multivariate logistic regression analysis identified four independent factors with p-value <0.05 (VCM concentration ≥20 mg/L, amphotericin B (AMPH-B), piperacillin-tazobactam (TAZ/PIPC), and vasopressor drugs). In Criterion 2, multivariate logistic regression analysis identified concomitant use of vasopressor drugs with p-value <0.05. Therefore, concomitant use of vasopressor drugs was suggested to affect the risk of VIN in patients aged 0-1 year. The findings may help in developing estimation models to assess the risk of VIN in paediatric patients.
万古霉素(VCM)诱导的肾毒性(VIN)是儿科患者的主要副作用。然而,大多数研究仅限于 0-18 岁的患者。我们使用日本电子病历数据库评估了 0-1 岁患者发生 VIN 的危险因素。我们使用 RWD 数据库,该数据库包含了来自 160 家医疗机构的约 2000 万人的电子病历和理赔数据。我们的目标是在 2000 年 6 月至 2020 年 12 月期间接受 VCM 治疗的住院患者。VIN 通过两个标准定义:标准 1 是 VCM 治疗期间血清肌酐(Scr)比基线增加≥0.5mg/dL 或 50%;标准 2 是 VCM 治疗期间 Scr 在七天内增加≥50%或 Scr 在两天内增加≥0.3mg/dL。使用多变量逻辑回归分析评估 VIN 的危险因素。我们分析了 446 名患者;标准 1 和标准 2 中的 VIN 患者分别为 33 名和 58 名。在标准 1 中,多变量逻辑回归分析确定了四个具有 p 值<0.05 的独立因素(VCM 浓度≥20mg/L、两性霉素 B(AMPH-B)、哌拉西林他唑巴坦(TAZ/PIPC)和血管加压药物)。在标准 2 中,多变量逻辑回归分析确定了血管加压药物的同时使用具有 p 值<0.05。因此,血管加压药物的同时使用提示可能会影响 0-1 岁患者发生 VIN 的风险。这些发现可能有助于开发评估儿科患者发生 VIN 风险的估算模型。